Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Bayer
Boehringer Ingelheim
Compass Therapeutics
M.D. Anderson Cancer Center
Compass Therapeutics
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Genentech, Inc.
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
National Cancer Institute (NCI)
Providence Health & Services
The Methodist Hospital Research Institute
OncoC4, Inc.
Genmab
USWM, LLC (dba US WorldMeds)
KaliVir Immunotherapeutics
Pfizer
Eastern Cooperative Oncology Group
Pfizer
Aulos Bioscience, Inc.
Ipsen
Sotio Biotech Inc.
Pfizer
Pfizer
Pfizer
M.D. Anderson Cancer Center
Mayo Clinic
Dragonfly Therapeutics
Stanford University
AstraZeneca
Seagen Inc.
Merck Sharp & Dohme LLC
Mayo Clinic
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
Neonc Technologies, Inc.
ViroMissile, Inc.
Erasca, Inc.
Kaiser Permanente
Pfizer
Radiopharm Theranostics, Ltd
Arvinas Inc.
Tizona Therapeutics, Inc
M.D. Anderson Cancer Center
Daiichi Sankyo